Caeregen Therapeutics is focused on discovering and developing novel drug therapies which repair, restore, and protect damaged and diseased tissues by reactivating the pathways and signaling which accompanies normal cellular and tissue development
December 8, 1946 – October 21, 2022. Dr. Trese was a great and inspirational leader, friend, and colleague whose warmth, wit, and generosity of spirit knew no boundaries.
PhD in Molecular Genetics and Microbiology (UF)− Director of Pediatric Retinal Disease Molecular Genetics Laboratory at Oakland University Eye Research Institute.
Associated Retinal Consultants, Royal Oak, MI−President, Pediatric Retinal Research Foundation−Extensive clinical trial experience.
Deep drug development back-ground, having ushered >25 drugs from various phases of development to commercial/clinical use−Former CEO/President, Multiple Myeloma Research Foundation.
Over 30 years conducting eye research. Spanning basic, translational and product development.
Expert in age-related macular degeneration Vice Chair for Research and founder of the Center for Advanced Vision Science, University of Virginia
Expert in diabetic retinopathy Director of Beetham Eye Institute at Joslin Diabetes Center, Harvard Medical School
Extensive innovations in intravitreal, gene and surgical adjuvant drug therapy. Founding Director of the Byers Eye Institute at Stanford
Discovered vascular endothelial growth factor (VEGF), Senior Deputy Director, Basic Science at UC San Diego
Expert in retinopathy of prematurity and vascular growth mechanisms. Professor of Ophthalmology, Harvard Medical School
Learn more about investing in our innovation.
It is with great sadness we announce the passing of Dr. Michael T. Trese, co-founder and Chief Technology Officer of Caeregen Therapeutics. Dr. Trese was one of the pioneers, leading innovators, and ...
Caeregen Therapeutics today announced the U.S. Food and Drug Administration (FDA) designated Noregen™ for treatment of Familial Exudative Vitreoretinopathy (FEVR) as a drug for “rare pediatric disease...
Update in Understanding and Managing FEVR New research approaches and potential therapeutics are moving the field toward improved care for these patients. By Kimberly A. Drenser, MD, PhD April 2022 Fa...